November 4, 2010
Preliminary data show an experimental therapeutic vaccine against hepatitis C virus boosted response rates by 12 percent compared with standard HCV treatment of ribavirin and pegylated interferon, researchers reported at the annual meeting of the American Association for the Study of Liver Diseases in Boston.
Paul Pokros, MD, of the Scripps Clinic in La Jolla, Calif., said the Phase II trial of 133 patients included those who were treatment-naive and those who had not responded to standard treatment. Results in both subgroups were similar to the overall outcome but did not reach statistical significance compared with standard treatment. However, the findings are enough to warrant continued development of GI-5005, a recombinant, inactivated yeast that expresses hepatitis antigens.
GI-5005 generated an immune response similar to that seen among patients who are able to clear HCV without medication -- a modest response to the viral envelope proteins and a robust response to the nonstructural proteins NS3 and NS5.
11.02.2010; Michael Smith
No comments have been made.
|Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds|
|Which HIV Treatment Regimens Are Recommended for Newly Diagnosed Patients?|
|Weekly PRO 140 Antibody Injections May Work as HIV Maintenance Therapy|
|This Week in HIV Research: Effects of Treatment on Arterial Inflammation; Mortality Rate After 5 Years of Treatment Not Impacted by Initial CD4 Count|
|Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early Study|